The UK-based pharmaceutical and biotechnology giant, announced on Thursday that the COVID-19 shot brought in $1.17 billion in sales in the first six months of 2021.
The Anglo-Swedish company said in a statement that the figure is based on deliveries of about 319 million doses around the world, which included $572 million of sales in Europe and $455 million in developing countries.
AstraZeneca now expects core earnings of $5.05 to $5.40 per share after the recent purchase of Alexion Pharmaceuticals, a rare medicines business.
Source: Jordan News Agency